FDA Determines Regulatory Review Period for ATRYN Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ATRYN, a human biological product, in accordance with patent extension regulations, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.